CinnaGen

CinnaGen is an Iran-based biotechnology and biopharmaceutical company established in 1994 by Hamid Mobtaker. Its activities have centered on the development and manufacture of biological medicines, recombinant proteins, biosimilar drugs, and laboratory diagnostic reagents intended for in-vitro use. The company forms part of Iran’s biotechnology and pharmaceutical sector, an industry that has developed domestic capabilities for producing complex biological products and reducing dependence on imported medicines. The company’s publicly documented business includes biosimilar and recombinant therapeutics as well as diagnostic products. One of its best-known products is Cinnovex, a biosimilar version of interferon beta used in the treatment of multiple sclerosis. The biological technology underlying Cinnovex was developed by scientists at Germany’s Fraunhofer Institute, which also carried out the initial testing. Fraunhofer licensed the relevant technology to CinnaGen, after which CinnaGen completed product development and secured approval from Iran’s Food and Drug Administration in 2007. CinnaGen has also been associated with the production and commercialization of products for markets beyond Iran. Reference material describes exports to other Middle Eastern countries and to countries in the Commonwealth of Independent States. This regional orientation reflects the company’s role as both a domestic biopharmaceutical producer and an exporter of biological and diagnostic products from Iran. During the COVID-19 pandemic, CinnaGen entered into a cooperation arrangement connected with Vaxine’s recombinant vaccine candidate, known as COVAX-19. Under the proposed arrangement, Phase 2 and Phase 3 clinical studies were to be initiated in Iran. If the studies and regulatory process were successful, CinnaGen was expected to manufacture the vaccine in Iran under the brand name SpikoGen and support its rollout in the Iranian market. The available reference material does not establish the final commercial or regulatory outcome of that arrangement. CinnaGen’s positioning is therefore based on biotechnology manufacturing, technology transfer, biosimilar development, and regional access to biological medicines and diagnostics. Publicly available material provides limited detail about its ownership, financial performance, senior-management structure, current product portfolio, and present international footprint. Those areas require further verification from company, regulatory, or corporate sources.

CinnaGen was founded in Iran in 1994 by Hamid Mobtaker. From its beginnings, the company developed within Iran’s emerging biotechnology and pharmaceutical ecosystem, where domestic production of biological medicines and laboratory technologies became strategically important. Its documented areas of activity include biosimilar drugs, recombinant proteins, and reagents used for in-vitro laboratory diagnostics. A significant stage in CinnaGen’s development was its collaboration with the Fraunhofer Institute in Germany. Fraunhofer scientists created the recombinant-DNA technology used for Cinnovex, a biosimilar form of interferon beta, and conducted the product’s initial testing. Following a licensing arrangement, CinnaGen took responsibility for completing development in Iran. The company obtained approval for Cinnovex from the Iranian Food and Drug Administration in 2007. The product is used in the treatment of multiple sclerosis and became a prominent example of CinnaGen’s ability to convert licensed biotechnology into an approved local pharmaceutical product. By 2016, available descriptions of the company identified three principal areas: biosimilar medicines, in-vitro diagnostic reagents, and recombinant proteins. CinnaGen also exported products beyond Iran, with reported markets in the Middle East and the Commonwealth of Independent States. These exports positioned the company as a regional supplier rather than solely a domestic manufacturer. During the COVID-19 pandemic, CinnaGen was linked to an agreement with Australia-based Vaxine concerning the recombinant vaccine candidate COVAX-19. The planned Iranian program involved Phase 2 and Phase 3 clinical trials. If the clinical and regulatory requirements were met, CinnaGen was expected to produce the vaccine in Iran under the name SpikoGen and make it available through the Iranian market. The supplied reference material does not provide enough information to confirm the full subsequent development, approval, manufacturing, or market performance of SpikoGen. Public references offer comparatively little information about CinnaGen’s corporate ownership, financial results, current executives, detailed manufacturing network, or complete product catalogue. Its documented history nevertheless shows a business model built around biopharmaceutical research and manufacturing, international technology cooperation, regulatory approval in Iran, and regional distribution of biological and diagnostic products.

• 2016

  Documented portfolio includes biosimilars and diagnostics

  [1]Cinnagenen.wikipedia.org

  Reference material described CinnaGen as manufacturing biosimilar drugs, in-vitro diagnostic reagents, and recombinant proteins, with exports to Middle Eastern and Commonwealth of Independent States markets.

• 2007

  Cinnovex receives Iranian approval

  [1]Cinnagenen.wikipedia.org

  CinnaGen completed development of Cinnovex, a biosimilar interferon-beta medicine, and obtained approval from Iran’s Food and Drug Administration.

• 1994

  Company founded

  [1]Cinnagenen.wikipedia.org

  Hamid Mobtaker founded CinnaGen in Iran.

• Cooperation on SpikoGen COVID-19 vaccine

  [1]Cinnagenen.wikipedia.org

  CinnaGen agreed to participate in Iranian clinical development and prospective production of Vaxine’s recombinant COVID-19 vaccine candidate under the SpikoGen brand.

Iranian biotechnology and biopharmaceutical manufacturer focused on biosimilars, recombinant biological products, in-vitro diagnostics, technology transfer, and regional market supply.

• Biosimilar medicine · 2007

  Cinnovex

  Cinnovex is a biosimilar version of interferon beta used in the treatment of multiple sclerosis. Its underlying recombinant-DNA technology was developed by scientists at the Fraunhofer Institute in Germany, which also conducted initial testing. Fraunhofer licensed the technology to CinnaGen, which completed development in Iran and obtained approval from the Iranian Food and Drug Administration in 2007.

• Recombinant COVID-19 vaccine

  SpikoGen

  SpikoGen was the planned Iranian brand for Vaxine’s recombinant COVID-19 vaccine candidate COVAX-19. CinnaGen was expected to conduct or support Phase 2 and Phase 3 clinical studies in Iran and, subject to successful trials and regulatory approval, manufacture the vaccine for the Iranian market. The supplied sources do not establish its final approval or commercial status.

• 2007

  Commercial and regulatory completion of CinnovexProduct launch

  Background

  CinnaGen received licensed recombinant-DNA technology from the Fraunhofer Institute for a biosimilar interferon-beta product intended for multiple-sclerosis treatment.

  Action taken

  The company completed product development in Iran and obtained approval from the Iranian Food and Drug Administration.

  Aftermath

  Cinnovex became a documented example of CinnaGen’s biosimilar-development and technology-transfer capabilities.

  Source

• Planned development and production of SpikoGenProduct launch

  Background

  Vaxine’s recombinant COVID-19 vaccine candidate was intended to undergo later-stage clinical evaluation in Iran.

  Action taken

  CinnaGen entered a cooperation arrangement to initiate Phase 2 and Phase 3 studies and potentially manufacture the vaccine under the SpikoGen name.

  Aftermath

  The available reference does not confirm the final clinical, regulatory, or commercial outcome.

  Source

• 2007

  CinnaGen developed Cinnovex, a biosimilar interferon-beta product[1]Cinnagenen.wikipedia.org

  Product launch · Regulation

  CinnaGen completed development of Cinnovex after receiving technology licensed from the Fraunhofer Institute and obtained approval from Iran’s Food and Drug Administration. The product is a biosimilar interferon-beta treatment for multiple sclerosis.

• CinnaGen planned Iranian development and production of SpikoGen[1]Cinnagenen.wikipedia.org

  Product launch · Other

  CinnaGen entered a cooperation arrangement with Vaxine concerning clinical development of the recombinant COVID-19 vaccine candidate COVAX-19 in Iran. Subject to successful trials and approvals, the vaccine was to be manufactured by CinnaGen under the SpikoGen brand.

1. 1Cinnagenen.wikipedia.org